臨床外科66巻7号

2011年07月発行

特集 術前薬物療法は乳癌手術を縮小させるか

今後の乳癌診療における術前薬物治療の位置づけ

著者： 池田正¹ 志賀千鶴子¹

所属機関： ¹帝京大学医学部外科

ページ範囲：P.876 - P.880

【ポイント】

◆術前化学療法は術後化学療法と効果は変わらず，術後化学療法が適応の患者には標準治療となろう．

◆多くの場合，縮小手術が可能となるが，切除範囲の決定には注意を要する．

◆センチネルリンパ節生検は化学療法前に施行するのが標準であるが，将来は大部分の症例では化学療法後に施行するようになるであろう．

参考文献

1）Early Breast Cancer Trialists' Collaborative Group（EBCTCG）：Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival：an overview of the randomised trials. Lancet 365：1687-1717, 2005

2）日本乳癌学会（編）：科学的根拠に基づく乳癌診療ガイドライン[1]薬物療法．2010年版．金原出版，2010，p15

3）Ikeda T, Jinno H, Matsui A, et al：The role of neoadjuvant chemotherapy for breast cancer treatment. Breast Cancer 9：8-14, 2002

4）Ikeda T, Jinno H, Kitajima M：The evolution of primary chemotherapy in breast cancer treatment. Breast Cancer 11：148-155, 2004

5）Rastogi P, Anderson SJ, Bear HD, et al：Preoperative chemotherapy：updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26：778-785, 2008

6）Mauriac L, MacGrogan G, Avril A, et al：Neoadjuvant chemotherapy for operable breast carcinoma larger than 3cm：a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein（IBBGS）. Ann Oncol 10：47-52, 1999

7）Jackisch C, von Minckwitz G, Eidtmann H, et al：Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer：second interim analysis. Clin Breast Cancer 3：276-280, 2002

8）Heys SD, Hutcheon AW, Sarkar TK, et al：Neoadjuvant docetaxel in breast cancer：3-year survival results from the Aberdeen trial. Clin Breast Cancer 3 Suppl 2：S69-74, 2002

9）Buzdar AU, Valero V, Ibrahim NK, et al：Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer：an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13：228-233, 2007

10）von Minckwitz G, Kümmel S, Vogel P, et al：Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer：phase Ⅲ randomized GeparTrio trial. J Natl Cancer Inst 100：542-551, 2008

11）Bhargava R, Beriwal S, Dabbs DJ, et al：Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy：a single institutional experience with 359 cases. Cancer 116：1431-1439, 2010

12）http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

13）Saeki T, Aogi K, Nakamura S, et al：A multicenter phase Ⅱ study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer. J Clin Oncol 28：15s, 2010

14）Luini A, Zurriada S, Galimberti V, et al：Radioguided surgery of occult breast lesions. Eur J Cancer 34：204-205, 1998

15）日本乳癌学会（編）：科学的根拠に基づく乳癌診療ガイドライン[2]外科療法．2008年版．金原出版，2008，pp8-9

16）Kinoshita T：Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer 14：10-15, 2007

17）Giuliano AE, Hunt KK, Ballman KV, et al：Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis：a randomized clinical trial. JAMA 305：569-575, 2011

18）Dowsett M, Dunbier AK：Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res 14：8019-8026, 2008